SCHEMBL14278140

SCHEMBL14278140

NOOSc1ccc(-n2nc(C(F)F)cc2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 17/20 0.60
▸ PTGS1 P23219 13/20 0.60
▸ ABCB11 O95342 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ RPA1 P27694 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280460 0.89 PTGS2 (0.60) PTGS2PTGS1ABCB11ALDH1A1CYP3A4
SCHEMBL13627353 0.81 PTGS2 (0.66) PTGS2PTGS1ABCB11ALDH1A1SMN1; SMN2
SCHEMBL8292457 0.80 PTGS2 (0.71) PTGS2PTGS1ALDH1A1RPA1SMN1; SMN2
SCHEMBL5698586 0.78 PTGS2 (0.67) PTGS2PTGS1RPA1SMN1; SMN2CYP1A2
SCHEMBL27584983 0.78 PTGS2 (0.67) PTGS2PTGS1RPA1SMN1; SMN2MEN1
SCHEMBL5698729 0.75 PTGS2 (0.67) PTGS2PTGS1ALDH1A1RPA1SMN1; SMN2
SCHEMBL212658 0.75 PTGS2 (1.00) PTGS2PTGS1ABCB11ALDH1A1
SCHEMBL6339240 0.75 PTGS2 (1.00) PTGS2PTGS1ABCB11ALDH1A1
Sulfamide SCHEMBL7159984 0.74 PTGS2 (0.76) PTGS2PTGS1ABCB11ALDH1A1MEN1
SCHEMBL8635509 0.73 PTGS2 (0.78) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 — — US disclosed
Send feedback